Abstract: A test method, a test apparatus, a test system, and a storage medium are provided, so as to solve the technical problem of how the leakage of a battery cell is detected. The test method of this embodiment of this application includes: (S10) obtaining a CAN signal output by a gas sensor, where the gas sensor is disposed on a test box, and a battery cell is placed in the test box; (S20) determining a gas concentration of a predetermined gas in the test box based on the CAN signal; and (S30) sending a concentration exceedance signal when the gas concentration is higher than a concentration threshold.

Abstract: Embodiments of this application provide a testing apparatus, configured to test a battery and including a test body and a first door body. The test body may include an accommodating cavity for accommodating the battery, and an opening. The opening may communicate with the accommodating cavity, and the first door body may be connected to the opening and capable of moving relative to the opening. The first door body may have a first state and a second state; in the first state, the first door body may block a part of the opening; and in the second state, the first door body may seal the opening.

Abstract: Disclosed in the present disclosure is a double-deck multi-span bridge construction method. According to the double-deck bridge construction method of the present disclosure, construction is carried out by using a method of disassembling a support jig frame in a graded and span-separated mode, an upper chord jig frame and a lower chord jig frame can be used in a recycle manner, and construction costs are reduced. In addition, a construction period of building the support jig frame is shortened, and other construction operations can be synchronously carried out on a span in which the jig frame is disassembled, for example, fire retardant coating construction can be carried out on a mounted bridge deck after the jig frame is disassembled, and the construction period of a double-deck multi-span bridge is effectively shortened.

Abstract: Provided are computing systems, methods, and platforms for negative sampling in knowledge graphs with improved efficiency. A knowledge graph comprising entities and links between the entities can be obtained. A query computation graph comprising nodes and edges can be generated based on the knowledge graph. The nodes of the query computation graph can include anchor nodes, a root node, and intermediate nodes positioned in paths between the anchor nodes and the root node. A node cut of a query of the query computation graph can be determined and can include at least one node that cuts at least one path between each anchor node and the root node of the query computation graph. Negative samples can be identified by bidirectionally traversing the query computation graph in a first direction from the anchor nodes to the node cut and in a second direction from the root node to the node cut.

Abstract: The present description relates to compounds of Formula (I), forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present disclosure is directed to machine learning model architectures which provide full attention capability in each attention head while maintaining low computation and memory complexity. Specifically, according to one aspect of the present disclosure, example attention models provided herein can treat the self-attention mechanism as a conditional expectation over embeddings at each location and approximate the conditional distribution with a structured factorization. Each location can attend to all other locations, either via direct attention, or through indirect attention to group representations, which are again conditional expectations of embeddings from corresponding local regions.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: One embodiment of a method for performing a task includes generating a first posterior distribution of a global latent context variable for the task based on a pool of contexts sampled from one or more previous episodes of the task. The method also includes generating a second posterior distribution of a local latent context variable for a current time step in a current episode of the task based on one or more recent contexts sampled at one or more previous time steps of the current episode. The method further includes causing an agent to perform an action related to carrying out the task based on the first posterior distribution, the second posterior distribution, and a current state associated with the current time step.

Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.

Abstract: Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Abstract: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.